Pre-existing anti-viral vector antibodies in gene therapy
|
|
- Noel Hart
- 6 years ago
- Views:
Transcription
1 Pre-existing anti-viral vector antibodies in gene therapy Impact on assays, study conduct and data interpretation Mark N Milton, Executive Director DMPK-Bx, Novartis AAPS NBC, May 2016
2 Gene Therapy Treatment of diseases caused by mutated genes A normal gene is added to enough somatic cells to restore normal function Viral vectors are commonly used to deliver the gene Viral vectors are derived from, or are, naturally occurring viruses - Adenovirus (e.g. Ad5) - Adeno-associated virus (e.g AAV2, AAV8) - There are over 100 natural AAV variants - AAV7, AAV8, and AAVrh10 were originally isolated from rhesus macaque tissues. 2 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
3 Diseases being treated by gene therapy Blood disorders and anemias Cancer Cardiovascular diseases Congenital blindness and eye diseases Type I diabetes Hemophilia Immunodeficiency diseases Infectious diseases Lysosomal storage disorders Musculoskeletal disorders Neurodegenerative and movement disorders Respiratory disorders 3 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
4 Routes of administration for gene therapies The challenge is to get the as much of the gene therapy as possible into the cells of interest 4 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
5 Challenges for Gene Therapies Immunogenicity The presence of pre-existing anti-viral vector antibodies may result in a sub-optimal, or no, therapeutic response. This is a concern for systemically administered gene therapies but of lesser concern for gene therapies administered into the target tissue Prevalence of pre-existing antibodies can be high There can be an acute reaction to the administration of the gene therapy as a consequence of the activation of the innate immune system However, this response is generally mild and resembles the response to a viral infection Since gene therapies are almost always administered once, the generation of treatment-boosted or treatment-emergent antibodies is of lesser concern 5 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
6 The seroprevalence of anti-viral vector antibodies Some factors that may impact seroprevalence Age Seroprevalence tends to be lower at birth and gradually increases to ~ 3 years of age The impact of age differs for different vectors Health status Incidence may be lower in patients with a compromised immune system compared to healthy volunteers Geographic location Tends to be higher in developing countries - May be due to living conditions, population density, hygienic conditions, different level of health care, MHC background or other factors 6 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
7 Seroprevalence of anti-aav1 antibodies High seroprevalence with regional variability Europe and Israel (N=618) United States (N=934) 7 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
8 Seroprevalence of anti-aav8 antibodies Highly variable between different geographical regions What is important is where the patients have been, not where they are now Population Region Incidence Healthy USA 15.7% Healthy USA Europe Australia 15-20% ~30% 25-30% ~25% Africa Healthy France 38% Healthy China 82% Healthy China 69% Healthy IBD patients Healthy Hemophilia Mucopolysaccharidosis VI (MPS VI) Netherlands 94% 70% Japan 32.9 % 32.9% Turkey 42% Netherlands Italy NOTE: Comparison across studies is fraught with difficulties due to the different assays used by different laboratories 8 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
9 Treatment failure of gene therapies Impact of pre-existing antibodies Diminished hepatocyte transduction in monkeys with preexisting anti-aav8 antibody titers > 1:10 after IV administration of AAV8 vector expressing green fluorescent protein Weak, decaying or no transgene expression in monkeys with pre-existing antibodies when administered AAV2 gene therapy by the intravitreal route Correlation shown between serum and vitreal titers of anti-aav2 antibodies Insufficient efficacy of AAV1 gene therapy administered directly into the human heart 9 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
10 Risk Mitigation Strategies Plasmapheresis Blood is removed and separated into plasma and blood cells. Blood cells are returned to the body, the plasma is disposed and an albumin solution is infused into the patient to replace the plasma volume removed. - May be useful for subjects with low levels of broadly cross-reacting anti-aav antibodies but might be insufficient for patients with high nab titers. Minimizing contact of vector with blood Administer directly into the target organ to avoid exposing the vector to the high levels of Nabs in blood. - Administer into the hepatic artery or portal vein (to target the liver) or intracoronary (to target the heart) or subretinal space (to treat ocular diseases) 10 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
11 Risk Mitigation Strategies Immunosuppression Lower Nab levels by depleting B-cells with drugs such as rituximab - CAVEAT: tolerogenic properties of AAV can be altered and an undesirable immune response to the transgene may be induced Saturation of pre-existing ADA Administration of empty capsids Select serotype to be used as vector based on prevalence of anti-vector antibodies in the intended patient population 11 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
12 Cynomolgus Monkey Serum Anti-AAV8 Antibody Assay Assay Format Sandwich ELISA assay format was used Empty viral capsid (GMP batch) coated on the ELISA plate / colorimetric detection Detected IgM and IgG antibodies Positive Control Commercially-available mouse reagent Negative Control (NC) Use of IgG-depleted serum (a common procedure to remove pre-existing Abs) was not feasible Generation of NC pool from sera with very low signal which was not specific for the viral capsid (i.e signal that was not reduced by addition of excess capsid) 12 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
13 Cynomolgus Monkey Serum Anti-AAV8 Antibody Assay Sample Analysis Screening assay was not performed Samples were directly run in the confirmatory assay Confirmatory cut point could not be established Global precision of the confirmatory assay (n=108) was 24% Any sample with a % inhibition > 24% was reported as positive for anti-aav8 Abs. Samples with % inhibition < 24% and high levels of anti-aav8 antibodies (OD>2) were reanalyzed diluted in the confirmatory assay Samples confirmed positive were analyzed in the titration assay: Two-fold dilution steps were used Only 4 dilutions used in order to maximize throughput 13 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
14 Titer Titer Pre-study anti-aav8 antibodies High incidence that varies between groups Day -20 Day Group 1 Group 2 Group 3 Group 4 Group 5 Unassigned 0 Group 1 Group 2 Group 3 Group 4 Group 5 Unassigned Group 1 Group 2 Group 3 Group 4 Group 5 Unassigned All Day -20 6/8 (75%) 2/2 (100%) 9/10 (90%) 10/10 (100%) 4/10 (40%) 6/6 (100%) 37/46 (80%) Day -13 6/8 (75%) 2/2 (100%) 8/10 (80%) 10/10 (100%) 5/10 (50%) 6/6 (100%) 37/46 (80%) 14 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
15 Titer Change in Titer with time Data from Control Group Antibody titers wax and wane over time in untreated animals Data from control animals can provide information that is useful for the interpretation of data from dosed animals A B C D E F G H Day Day Day Day Day <1 0 Day Day A B C D E F G H Day <1 0 Day Study Week 15 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
16 Cynomolgus Monkey Serum Anti-AAV8 Antibody Assay Learnings Sample analysis Sample analysis timelines will be long (low throughput assay) 89% of the samples were confirmed positive and analyzed in the titer assay (4 dilutions) >150 samples had to be repeated at higher dilutions A calibration-curve based format would have been preferable, especially when a high number of samples have to be analyzed. Use larger dilution steps (e.g. 4x or 8x rather than 2x) Sample with titers > 1024 were not reanalyzed at further dilutions but reported as > 1024 and extrapolated to 2048 for graphical representation. Directly titer the anti-vector antibodies (no screening nor confirmatory assays). Plan for large amounts of reagents Over 80 vials of vg/ml were required for assay development, assay validation and sample analysis Two new pools of NC had to be prepared and qualified during sample analysis Establish plan for data analysis ahead of time Define fold-change in titer to define treatment-emergent ADA Create plan for graphical representation of data 16 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
17 Cynomolgus Monkey Serum Anti-AAV8 Antibody Assay Learnings Study Design and Data Analysis Collect multiple pre-dose samples to better understand prevalence of pre-existing Abs Screen animals prior to study dosing and exclude animals with pre-existing antibodies (dependent upon route of administration) If necessary, consider assigning animals to dose groups based upon their Ab status and titer Utilize the control group to monitor the health of the animals (i.e. use the control group as sentinels for viral infections) Establish plan for data analysis ahead of time Define fold-change in titer to define treatment-emergent ADA Create plan for graphical representation of data 17 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
18 Application to Clinical studies Collect multiple pre-dose samples to better understand prevalence of preexisting Abs Do not simply rely on demographic information Sampling should occur as close to dosing as possible Screen patients prior to study dosing and either exclude patients with preexisting antibodies (dependent upon route of administration) or institute techniques to reduce levels of pre-existing Abs (e.g. plasmapheresis) Consider collecting samples from people in the community in order to monitor the development of anti-viral vector antibodies as a result of a viral infection (sentinel patients) 18 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
19 Acknowledgements Lydia Michaut Tim MacLachlan 19 Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
20 References Calcedo R and Wilson JM (2013). Humoral immune response to AAV. Frontiers in Immunology, 4: 341 Greenberg B, Buler J, Felker GM et al (2016). Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart disease. Gene Therapy, 23: Kotterman MA, Yin L, Strazzeri JM et al (2015). Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to nonhuman primates. Gene Therapy, 22: Monteilhet V, Saheb S, Boutin S et al (2011). A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6 and 8. Molecular Therapy, 19: Wang L, Calcedo R, Bell P et al (2011). Impact of pre-existing immunity on gene transfer to nonhuman primate liver aith adeno-associated virus 8 vectors. Hum Gene Ther, 22: Pre-existing anti-viral vector antibodies in gene therapy Mark N Milton May 2016 AAPS NBC Business Use Only
Development of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies
Development of Multiplex Sensitive Anti-Drug Antibody Assays for CRISPR/Cas9 Gene Therapies September 27, 2017 Junxia Wang editasmedicine.com 1 Overview of the presentation Immunogenicity Introduction
More informationGlobal Leader in Viral Vector Technologies
Global Leader in Viral Vector Technologies Gene Therapy Vaccines - Discovery 1 SIRION BIOTECH ANY GENE TO ANY CELL Expert for viral vectors Competitive proprietary viral vector platforms High-end enabling
More informationLow Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans
Low Seroprevalence of Neutralizing Antibodies Targeting Two Clade F AAV in Humans Jeff L. Ellsworth,* Michael O Callaghan, Hillard Rubin, and Albert Seymour Homology Medicines, Inc., Bedford, Massachusetts.
More informationPassive Immunization Trials to Inform Vaccine Design
Passive Immunization Trials to Inform Vaccine Design Points for Consideration from deliberations held at the August 8, 2014 workshop Contents I. Introduction... 2 II. Types of trials... 2 1. Therapeutic
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationIssues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University
Issues in production of viral gene transfer vectors Stefan Kochanek Department of Gene Therapy Ulm University Only few positive results in gene therapy so far - many early phase, few late phase clinical
More informationANTIBODY IMMUNOGENICITY
ANTIBODY IMMUNOGENICITY Tolerance Classical Immunity To aggegated Antibody Chiller and Weigle, PNAS, 65:551, 1970; Benjamin and Waldmann, et al, J Exp Med, 163:1539, 1986) THE IMMUNOGENICITY PROBLEM WITH
More informationComparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm
Comparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm Jarrod Dean Principal Research Associate, Analytical Development Sanofi Presented by GTC, a
More informationuniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients
More informationThe presenter declare no conflict of interest This work was partly supported by Selecta Bioscience
Modulation of AAV vector dosing and avoidance of capsid immune responses via repeated co-administration of vector with rapamycin tolerogenic nanoparticles Amine Meliani The presenter declare no conflict
More informationChapter 17: Immunization & Immune Testing. 1. Immunization 2. Diagnostic Immunology
Chapter 17: Immunization & Immune Testing 1. Immunization 2. Diagnostic Immunology 1. Immunization Chapter Reading pp. 505-511 What is Immunization? A method of inducing artificial immunity by exposing
More informationStrategies to Improve Drug Tolerance in Nab Assays
Strategies to Improve Drug Tolerance in Nab Assays Steven J Swanson, PhD Senior Vice President, Research ImmunoCellular Therapeutics Ltd steven.swanson@imuc.com AAPS National Biotech Conference June 2015
More informationRevised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion
Revised Immunogenicity Guideline: Assays and methods- Presentation of the draft guideline and introduction of the topics for discussion Robin Thorpe & Meenu Wadhwa Revised Guideline: Differences from original
More informationTarget/drug interference considerations in immunogenicity assessment
Target/drug interference considerations in immunogenicity assessment Eric Wakshull, PhD Senior Scientist March 9, 2016 EMA Workshop on Immunogenicity Outline Page 2 Basic Immunogenicity screening assay
More informationDesign and Validation of a Non Cell-based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic
Design and Validation of a Non Cell-based Receptor Binding Assay for the Detection of Neutralizing Antibodies to a Biological Therapeutic Shalini Gupta Associate Director Amgen, Thousand Oaks, CA shalinig@amgen.com
More informationPeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay
PeliClass human IgG subclass ELISA kit Enzyme-linked immunosorbent assay Catalog No: M1551 Size: six pre-coated 8-well strips for each of the four IgG subclasses Test description The PeliClass human subclass
More informationManufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective
Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective CASSS CMC Summer Forum 2017 Chris Storbeck, PhD Health Canada Outline Health Canada organization Regulation of
More informationOIE Guideline. International Reference Antibody Standards for Antibody Assays. 1. Introduction
OIE Guideline International Reference Antibody Standards for Antibody Assays 1. Introduction 1.1. Purpose This document provides guidelines for the preparation, validation and distribution of antibodies
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationAn innovative approach for detecting NAb directed to antibodyderived therapeutics based on the bridging ADA assay
Nanobodies Innovative therapeutics An innovative approach for detecting NAb directed to antibodyderived therapeutics based on the bridging ADA assay Lieselot Bontinck, Scientist Outline Background Ablynx
More informationsirna Overview and Technical Tips
1 sirna Overview and Technical Tips 2 CONTENTS 3 4 5 7 8 10 11 13 14 18 19 20 21 Introduction Applications How Does It Work? Handy Tips Troubleshooting Conclusions Further References Contact Us 3 INTRODUCTION
More informationMouse Interferon alpha ELISA Kit
Mouse Interferon alpha ELISA Kit Catalog No: CK2010-1 Size: 1 x 96 tests CK2010-5 5 x 96 tests Range: 12.5-400 pg/ml Specifications: This kit quantitates interferon alpha in tissue culture media (10% FBS)
More informationUpdate from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products
Update from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products Peter Marks, M.D., Ph.D. FDLI 2017 Outline Products regulated Significance of
More informationJ. Fraser Wright, Ph.D.
Towards Better Characterization of Recombinant AAV Gene Transfer Vectors: Case Studies Illustrating Challenges with Dose Determining Vector Concentration methods J. Fraser Wright, Ph.D. Well Characterized
More informationStep-by-Step Description of ELISA
Step-by-Step Description of ELISA The protocols in this kit rely on indirect antibody capture ELISA. The steps in this assay are: Step 1: Antigen is added to the wells of the microplate strip and incubated
More informationPhase 1 SMA Type 2 Trial Initiation and Study Design. December 2017
Phase 1 SMA Type 2 Trial Initiation and Study Design December 2017 Disclaimers This presentation contains forward-looking statements, including statements about: the timing, progress and results of preclinical
More informationSVANOVIR APV-Ab. Avian Pneumovirus Antibody Test
Avian Pneumovirus Antibody Test Contents Microtitre plate Microtitre plates (96 wells) coated with non-infectious APV antigen (sealed and stored dry) Conjugate Lyophilised (horseradish peroxidase conjugated
More informationThe Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis
The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis Christelle Pythoud, PhD 2 nd EBF YSS, Barcelona Spain Celerion Switzerland
More informationcolorimetric sandwich ELISA kit datasheet
colorimetric sandwich ELISA kit datasheet For the quantitative detection of mouse Interleukin 6 (IL6) concentrations in serum, plasma and cell culture supernatants. general information Catalogue Number
More informationAdeno-Associated Virus titer and aggregation characterization
Adeno-Associated Virus titer and aggregation characterization Characterization of gold-labeled Adeno-Associated Virus (AAV) and other small viruses by Nanoparticle Tracking Analysis (NTA) PARTICLE CONCENTRATION
More informationOverview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations. Audrey Chang, PhD, Senior Director Development Services
Overview of Biologics Testing and Evaluation: Regulatory Requirements and Expectations Audrey Chang, PhD, Senior Director Development Services Definition of Biologics: PHS Act, section 351 Virus, therapeutic
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationCurrent situation on nonclinical safety evaluation of regenerative medical products in Japan
Current situation on nonclinical safety evaluation of regenerative medical products in Japan Takuya Nishimura Office of Cellular and Tissue based Products PMDA Disclaimers The views expressed in this presentation
More informationCyfra 21-1 IRMA. Product information Information about other products is available at: Userś Manual DE52100
Product information Information about other products is available at: www.demeditec.com Userś Manual Cyfra 21-1 IRMA The CYFRA 21.1 IRMA system provides a direct in vitro quantitative determination of
More informationAssays for Immunogenicity: Are We There Yet?
Assays for Immunogenicity: Are We There Yet? Mark Wener, MD Department of Laboratory Medicine & Rheumatology Division Department of Medicine University of Washington Seattle, WA 98195 wener@uw.edu Goals:
More informationB-cell Epitope Prediction and Cloning monoclonal ADAs
B-cell Epitope Prediction and Cloning monoclonal ADAs Stefan Ryser, CEO, Trellis Bioscience 3 rd International Symposium on Higher Order Structure of Protein Therapeutics Arlington, Virginia, February
More informationOvercoming drug & target interference in ADA and nabassays
Overcoming drug & target interference in ADA and nabassays Robert Nelson Ph.D. MRQA Head of Bioanalytical Laboratory, Novimmune SA 1 Presentation Outline Case Study 1 Drug & target interference in a clinical
More informationCHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS
CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS Maria Cristina Galli, Ph.D. Istituto Superiore di Sanità Roma, Italy EATRIS ATMP platform chair ISCT 2016 Global Regulatory Perspective Workshop
More informationRegulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products
Regulatory considerations for manufacturing and testing of investigational chimeric antigen receptor (CAR) T-cell products Xiaobin Victor Lu Product Reviewer Gene Therapies Branch DCGT/OCTGT/CBER/FDA MEASUREMENT
More informationPassive vaccination as a global strategy for preventing RSV disease in infants. Filip Dubovsky MD MPH FAAP MedImmune March 2016
Passive vaccination as a global strategy for preventing RSV disease in infants Filip Dubovsky MD MPH FAAP MedImmune March 2016 Outline for Presentation Rationale for passive immunization for RSV prophylaxis
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More informationHuman IL-6 ELISA. For the quantitative determination of IL-6 in human cell culture supernates, serum and plasma (heparin, EDTA, citrate)
K-ASSAY Human IL-6 ELISA For the quantitative determination of IL-6 in human cell culture supernates, serum and plasma (heparin, EDTA, citrate) Cat. No. KT-1348 For Research Use Only. Not for diagnostic
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationGREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014
GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014 1982 WHAT HAS HAPPENED SINCE IN TECHNOLOGY ASSESSMENT AND. US Orphan Drug
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular
More informationAssays and Strategies for Immunogenicity Assessment. Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen
Assays and Strategies for Immunogenicity Assessment Steven J Swanson, Ph.D. Executive Director, Medical Sciences Clinical Immunology, Amgen General Antibody Assay Strategy Correlation of clinical findings
More informationTogether, all nine participants have reduced infusions of factor IX concentrates by 99 percent over cumulative 1,650 days
Spark Therapeutics and Pfizer Present Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at Annual ASH Meeting Together, all nine participants
More informationGMO Technology Conference
GMO Technology Conference The regulation of Clinical Trials on humans involving therapies containing or consisting of genetically modified organisms The Printworks, Dublin Castle 10 th & 11 th October
More information2017 Well Characterized Biological Products
2017 Well Characterized Biological Products Gene Therapy Treatments for Hemophilia A & B Process Validation Considerations in the Manufacturing of Gene Therapy Products Robert Baffi, Ph.D., MBA Executive
More informationImmunological Techniques in Research and Clinical Medicine. Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016
Immunological Techniques in Research and Clinical Medicine Philip L. Cohen, M.D. Chief of Rheumatology, LKSOM 10 March 2016 Antibodies Remarkable Tools for Research and Diagnosis You can make an antibody
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationImmunogenicity Assay Considerations
Immunogenicity Assay Considerations Jochem Gokemeijer Jochem.gokemeijer@bms.com Bioassays and Bioanalytics Method Development, Berkley CA October 8 th 2013 Multi Tiered Immunogenicity Assay Approach Screening
More informationHerpes Simplex 1 IgM (HSV1 IgM)
DIAGNOSTIC AUTOMATION, INC. 23961 Craftsman Road, Suite D/E/F, Calabasas, CA 91302 Tel: (818) 591-3030 Fax: (818) 591-8383 onestep@rapidtest.com technicalsupport@rapidtest.com www.rapidtest.com See external
More informationWe are committed to translating ground-breaking science into genomic therapies that transform patients lives
We are committed to translating ground-breaking science into genomic therapies that transform patients lives Liver-based expression of the human alpha-galactosidase A gene (GLA) in a murine Fabry model
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationRegulatory Requirements for CRISPR Therapeutics. Bill Lundberg, MD February 2017
Regulatory Requirements for CRISPR Therapeutics Bill Lundberg, MD February 2017 Forward Looking Statements This document contains forward-looking statements within the meaning of the safe harbor provisions
More informationReference Materials for Adeno-Associated Viruses
Reference Materials for Adeno-Associated Viruses : Recommendations of the Quality Control Sub-Committee John Chiorini (NIH-NIDCR) Paul Husak (Cell Genesys) Gabrielle Kroener-Lux (Progen) James Marich (Cell
More informationConference call transcript for the March 2017 Quarterly Report
ASX ANNOUNCEMENT Conference call transcript for the March 2017 Quarterly Report Sydney Australia, 31 May 2017: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today lodged its transcript
More informationPRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016
PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016 1 FROM DISCOVERY TO COMMERCIALIZATION At least 10 years on average Average spend of $1.4B Less than 12% of drugs entering Phase I are approved
More informationAntibody-Drug Conjugate Bioanalytical Assay Development:
Antibody-Drug Conjugate Bioanalytical Assay Development: Immunogenicity Challenges November 16, 2016 Presented by Corinna Fiorotti, Ph.D. Presentation Overview ADC Overview ADC Assays ADC Immunogenicity
More informationOncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges
The content of this presentation reflects the opinion of the speaker and does not necessarily represent the official position of CDER Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory
More informationAntibody-based HLA (Human Leucocyte Antigen ) tissue-typing technologies
Human AB Serum Product Description Human AB Serum is a vital cell culture reagent for some human cell types providing growth factors, vitamins, nutrients as well as trace elements and transport factors,
More informationImmunogenicity Assessment - Challenges and Strategies
Immunogenicity Assessment - Challenges and Strategies 17Nov2015 Manju Saxena, Ph.D. Scientific Director Intertek Pharmaceutical Services 1 Presentation Outline Introduction Immunogenicity Testing (ADA
More informationClassification under the IVD Regulation
Classification under the IVD Regulation Nick Baker Head of IVD Notified Body LRQA Ltd Improving performance, reducing risk IVD regulation shift in regulatory scrutiny Under the current IVD directive 10-15%
More informationNASDAQ: ABEO
NASDAQ: ABEO www.abeonatherapeutics.com 1 Safe Harbor Statement This presentation contains certain statements that may be forward-looking within the meaning of Section 27a of the Securities Act of 1933,
More informationRecombinant Antibody Production in Therapeutic Antibody Projects. Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016
Recombinant Antibody Production in Therapeutic Antibody Projects Keshav Vasanthavada Senior Marketing Specialist, GenScript April 7, 2016 Presentation Outline 1 2 3 4 5 Introduction Recombinant Ab Production
More informationAssessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells
Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells David M, Hambly, Ph.D. Director, Analytical Development April 4th, 2016 Forward Looking Statements/Safe
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationRequirements for Yellow Fever Vaccine (Requirements for Biological Substances No. 3) Proposed Amendment
ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 13 to 17 October 2008 Requirements for Yellow Fever Vaccine (Requirements for Biological Substances No. 3) Proposed Amendment NOTE:
More informationQualifying SPR immunogenicity assays Dr. Christian Kühne
Qualifying SPR immunogenicity assays Dr. Christian Kühne Bioagilytix / IPM Biotech global CRO for large molecule bioanalysis supporting pre-clinical & clinical studies Biomarker, Pharmacokinetics, Immunogenicity
More informationHOST DEFENSE SMALL GROUP PROBLEM SOLVING SESSION CLINICAL IMMUNOLOGIC ASSAYS-II
HOST DEFENSE SMALL GROUP PROBLEM SOLVING SESSION CLINICAL IMMUNOLOGIC ASSAYS-II Monday, March 24, 2008 2:00 PM 4:00 PM Small Group Classrooms LEARNING GOAL Understanding in vitro assessment of immunologic
More informationBalanCD HEK293 SYSTEM
BalanCD HEK293 SYSTEM Maximize productivity in suspension cultures Versatile formulation supports transfection and production including: - Rapid, scalable production of viral vectors - Use the same system
More informationOncology for Scientists Christopher Choi, PhD Director, TCPF Assistant Professor of Oncology
Oncology for Scientists Christopher Choi, PhD Director, TCPF Assistant Professor of Oncology Immunological Battle Ground Tumor immunity Tumor growth The tumor environment is an immunological battle ground:
More informationThe Elite Provider. Cell & Gene. Therapy Manufacturing
The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Nathwani AC, Tuddenham EGD, Rangarajan S, et al. Adenovirus-associated
More information**MATERIAL SAFETY DATA SHEET**
Date Issued: August 19, 2009 Version: 5.0 Supersedes: August 8, 2006 Page 1 of 5 Section 1 Product and Company Identification Product Name: Herceptin Chemical Name: Anti-p185 HER2 Chemical Family: High
More informationFor the quantitative detection of human IL6 in serum, plasma, cell culture supernatants and urine.
m andw da a For the quantitative detection of human IL6 in serum, plasma, cell culture supernatants and urine. general information Catalogue Number Product Name Species cross-reactivity Range (calibration
More informationH-ferritin (Human) ELISA Kit
H-ferritin (Human) ELISA Kit Catalog Number KA0211 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of
More informationUpdate on the IVDR. Sue Spencer
Update on the IVDR Sue Spencer Caution The new regulations are draft the principles have now been agreed but the Annexes are subject to minor changes Further details will be added later pre and post application
More informationIG Production and Safety
IG Production and Safety Platelet Disorder Support Association July 20, 2013 Mary Gustafson, Vice President, PPTA Global Regulatory Policy Presentation Outline Introduction - PPTA Plasma Collection Final
More informationDevelopment Stage of Therapeutic Vaccines: The Regulator s View
Development Stage of Therapeutic Vaccines: The Regulator s View Thomas Hinz Head, Section Therapeutic Vaccines Paul Ehrlich Institute, Germany thomas.hinz@pei.de 1 DISCLAIMER This is the personal views
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationGuideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use.
1 2 3 18 November 2010 EMA/CHMP/BMWP/86289/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical
More informationRabies Potency Testing
www.pei.de Rabies Potency Testing Regulatory Perspectives and Experiences in the Establishment of a Serological Assay Dr Constanze Goepfert Section Viral Vaccines Laboratory Head Das Paul-Ehrlich-Institut
More informationPD-1 Pathway Recombinant Protein Collection
Pathway Recombinant Protein Collection www.acrobiosystems.com Content I. Introduction II. Biotinylated Pathway Proteins IIa. ELISA IIb. FAC Sorting IIc. Biopanning III. HPLC-verified Proteins IV. Full-length
More informationHuman IgG Rubella ELISA Kit
Human IgG Rubella ELISA Kit Catalog No: IRAPKT2020 Lot No: SAMPLE INTENDED USE The Rubella IgG ELISA is intended for use in evaluating a patient s serologic status to the rubella virus infection. It is
More informationFDA Perspective on the Preclinical Development of Cancer Vaccines
FDA Perspective on the Preclinical Development of Cancer Vaccines Richard D. McFarland Ph.D., M.D. Medical Officer CBER/OCTGT/DCEPT mcfarlandr@cber.fda.gov Cancer Vaccine Clinical Trials Workshop Alexandria,
More informationMyBioSource.com. Human VEGF ELISA Kit
Human VEGF ELISA Kit Catalog No.: MBS355343 Size: 96T Range: 31.2 pg/ml-2000 pg/ml (human serum, plasma, body fluids) 15.6 pg/ml-1000 pg/ml (cell culture supernates) Sensitivity < 1 pg/ml Storage and Expiration:
More informationDo Donors With Non-Deletional Blood Group O Allels Boost Anti-A and Anti-B Titers in Blood Group O Recipients?
Do Donors With Non-Deletional Blood Group O Allels Boost Anti-A and Anti-B Titers in Blood Group O Recipients? E. A. Scharberg, S. Seyboth, K. Panter, A. Ernst, J. Hagel, E. Richter, G. Rink, K. Janetzko,
More information1 R01 AI VMD HALFORD, W
1 R01 AI104935-01 2 VMD 1R01AI104935-01 ILLIAM CRITIQUE 1: Significance: 5 Investigator(s): 2 Innovation: 5 Approach: 8 Environment: 2 Overall Impact: This application proposes to develop a recombinant
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationOffice for Human Subject Protection. University of Rochester
POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,
More informationDiscovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A
Discovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A Contacts: Marty Simonetti martysimonetti@gmail.com Kirby Alton kirby.alton@abeomecorp.com Rick Shimkets
More informationCase Study: Examples Relating to the Quality Control of Cell-based Products
Case Study: Examples Relating to the Quality Control of Cell-based Products CMC Strategy Forum Japan 2014 Yuuki Miyatake1), 2) 1) TEIJIN PHARMA LIMITED 2) Japan Pharmaceutical Manufacturers Association
More informationHuman Serum Albumin Assay
Human Serum Albumin Assay Immunoenzymetric Assay for the Measurement of Human Serum Albumin Catalog # F055 Intended Use This kit is intended for use in quantitating human albumin (HSA). The kit is for
More informationHuman IL10RB ELISA Pair Set ( CRFB4 )
Human IL10RB ELISA Pair Set ( CRFB4 ) Catalog Number : SEK10945 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the
More informationThe Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors
Venkat Living Venkat with Hemophilia Living with Hemophilia The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors Tami Livnat 1, Alfica
More information